Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem

Shots: Frontier has granted LG Chem an exclusive global license to develop & commercialize FMC-220 outside of Greater China, with Frontier retaining full rights in Greater China As per the deal, LG will handle regulatory filings, global clinical development, & commercialization in licensed regions, while Frontier may partially fund confirmatory trials & receive upfront, clinical,…

ByRidhi RastogiApril 1, 2026

NEWS

Biogen to Acquire Apellis Pharmaceuticals for ~$5.6B

Shots: Biogen to acquire Apellis, incl. its assets Empaveli, Syfovre & felzartamab, for $41/share plus a non-transferable CVR, representing an upfront equity consideration of ~$5.6B, with remaining shares acquired later via a second-step merger CVR holders will receive $2/CVR if Syfovre achieves $1.5B sales (2027-2030), an additional $2 if it reaches $2B in the same…

ByRidhi RastogiApril 1, 2026

NEWS

Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence

Shots: The US FDA has granted clearance to Elitone for Men to help restore bladder control after prostate surgery, with US availability expected in Apr 2026 Elitone for Men is a non-invasive, at-home therapy that delivers neuromuscular stimulation to strengthen pelvic floor muscles, improving bladder control, with a simple 20min. daily use enabling consistent treatment…

ByRidhi RastogiApril 1, 2026

NEWS

Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune

Shots: Infinimmune has partnered with Merck to discover & develop antibody candidates against multiple undisclosed targets selected by Merck using Infinimmune’s human-first antibody discovery platform As per the deal, Infinimmune will use its Anthrobody discovery platform & Glimpse antibody language model to discover & optimize antibodies from human immune repertoires, enabling large-scale B-cell screening to…

ByRidhi RastogiApril 1, 2026

NEWS

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals incl. its asset cleminorexton & ORX142, expanding Lilly's neuroscience portfolio & capabilities into sleep medicine As per the deal, Lilly will acquire all issued & to-be-issued share capital of Centessa (incl. ADSs) for $38/share in cash (~$6.3B upfront), plus a non-transferable CVR of…

ByRidhi RastogiMarch 31, 2026

NEWS

Blackstone Closes $6.3B BXLS VI Fund, Making it the Largest Life Sciences Vehicle

Shots: Blackstone has closed Blackstone Life Sciences VI (BXLS VI) at its hard cap of $6.3B of total capital commitments, making it ~40% larger than its predecessor vehicle Blackstone launched BXLS platform in 2018, with ~$15B in assets under management as of Q4’25 & invests across the lifecycle of drugs and medtech, with an ~86%…

ByRidhi RastogiMarch 31, 2026

NEWS

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Shots: Recordati has received a non-binding indication of interest from CVC Capital Partners for a voluntary tender offer to acquire all outstanding shares & delist the company, subject to due diligence, financing, & partner identification Recordati expanded into rare diseases with its 2021 acquisition of EUSA Pharma for ~$845M, strengthening its rare cancer portfolio The…

ByRidhi RastogiMarch 31, 2026

NEWS

Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia

Shots: Trial assessed enlicitide (QD, PO) vs non-statin therapies (PO) added to background statins in adults with hypercholesterolemia & ASCVD risk or history, meeting its 1EP with a 64.6% LDL-C reduction at 8wks. & reductions of 56.7% vs bempedoic acid, 36% vs ezetimibe, & 28.1% vs their combination Trial also showed 8wk. reductions in ApoB…

ByRidhi RastogiMarch 31, 2026

NEWS

Teva Advances Biosimilars Portfolio with Ponlimsi (Denosumab) FDA Approval and Dual Omalizumab Filing Acceptance

Shots: The US FDA has approved Ponlimsi, a biosimilar version of Prolia (denosumab), for all indications of the reference product Approval was based on extensive clinical data, incl. analytical & clinical studies, which showed comparable efficacy, safety, & immunogenicity of Ponlimsi to the reference product Additionally, Teva’s biosimilar of Xolair (omalizumab) was accepted for review…

ByRidhi RastogiMarch 31, 2026

NEWS

BMS Reports P-III (SCOUT-HCM) Trial Data on Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Shots: BMS has reported the 28wk. P-III (SCOUT-HCM) trial data assessing Camzyos (mavacamten) vs PBO in 44 pts (12 to <18yrs.) with symptomatic oHCM & NYHA class II-III symptoms, with plans to present 56wk. data in a future conference Trial met its 1EP, showing reductions in Valsalva LVOT gradient at Wk. 28, supported by more pts…

ByRidhi RastogiMarch 31, 2026

Ridhi Rastogi

Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem

Biogen to Acquire Apellis Pharmaceuticals for ~$5.6B

Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence

Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Blackstone Closes $6.3B BXLS VI Fund, Making it the Largest Life Sciences Vehicle

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia

Teva Advances Biosimilars Portfolio with Ponlimsi (Denosumab) FDA Approval and Dual Omalizumab Filing Acceptance

BMS Reports P-III (SCOUT-HCM) Trial Data on Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Contact US

FOLLOW US